USPTO serial 79198534
RELIEF THERAPEUTICS
Reviewed by CopyMark Law Group
Reg. 5505300Status 709
- Filing date
- Status date
- Registration date
- Jul 3, 2018
- Examiner
- LAM, HAI-LY HUYNH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RELIEF THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C1100 New York Avenue, NWWashington, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary products, namely, prescription drugs for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; diagnostic products for medical use, namely, diagnostic preparations and reagents for the diagnosis of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; medicinal preparations and substances, namely, protein supplements, peptides from synthetic sources or extracted from natural organisms for the treatment of pulmonary affections, diabetic complications, neuropathies, allergies, and inflammation, and small chemical molecules from synthetic or natural sources for the treatment of pulmonary affections, diabetic complications, neuropathies, allergies, and inflammation ; biochemical preparations for medical or veterinary use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biological and chemical reagents for medical or veterinary use; biological preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; chemical preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biotechnological preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biotechnological products for medical use, namely, prescription drugs for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; medical diagnostic products, namely, diagnostic preparations and reagents for the diagnosis of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biomarkers for medicine, namely, diagnostic biomarker reagents for medical purposes | SECTION 71 - CANCELLED | — |
| 035 | Business consulting; project management services for others for business purposes; business consultancy services; compilation and management of computerized databases and central data files in the field of medicine; compilation of statistics; collection and systematization of data in a central file; business information, namely, provision of commercial information in the field of pharmaceutical products and provision of commercial information for consumers relating to medical and scientific research in the field of pharmaceutical products | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, scientific and pharmaceutical research, testing the efficacy, safety and tolerability of pharmaceuticals, and pharmaceutical drug development as well as new product research and design relating thereto; industrial analysis and research services in the field of pharmaceuticals, medical diagnostic preparations, and biotechnology; scientific research and development and medical research and development in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; research and development in the field of biotechnology; research in the fields of chemistry and biology; research in the field of biochemistry; scientific research for medical purposes; research and development in the field of diagnostic preparations; product development consulting; research and development of products; pharmaceutical research and development services; computer-aided scientific research, testing and analysis services in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; conducting of scientific feasibility studies; scientific analyses in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; scientific research, testing and analysis services in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; services provided by consultants in the field of scientific and industrial research, namely, research and development of new therapeutic pharmaceutical preparations; preparation of reports relating to scientific research; providing scientific research information in the form of scientific reports; provision of information and data relating to scientific and technological research and development in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; providing research information and results in the fields of biotechnology, science and medicine from an on-line searchable database; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; scientific research services for third parties in the field of biotechnology; design and development of computer hardware and software; development and research of products for third parties; consultancy services relating to biotechnology; analysis services, namely, consulting services in the fields of biotechnology, pharmacotherapy research and development, diagnostics, and pharmaceutical research and development; pharmaceutical and biological development and research services for third parties; clinical research in the field of treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; evaluation of pharmaceutical products; research in the field of pharmaceutical products; laboratory research in the field of medicinal and analytical chemistry, biology, pharmacology and toxicology; clinical development services, namely, research and development of new therapeutic pharmaceutical preparations; none of the foregoing for clinical trials on safety and effectiveness of drugs, apremilast, drugs for Behçet's disease, or for providing medical and scientific research information in the field of clinical trials | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Relief Therapeutics Holding S.A.
- Other trademarks owned by Relief Therapeutics S.A.
- Other trademarks owned by Relief Therapeutics S.A.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named RELIEF THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Mar 4, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Mar 4, 2026 | INPC | INVALIDATION PROCESSED | — |
| Sep 17, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 17, 2025 | C71T | CANCELLED SECTION 71 | — |
| Jun 1, 2024 | PRA7 | REGISTERED - SEC. 7 REQUEST ABANDONED | — |
| Jul 3, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 24, 2022 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Aug 16, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 16, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Mar 22, 2022 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Feb 18, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 20, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 20, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 20, 2022 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Jan 20, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 20, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 20, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 26, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 5, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 5, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 3, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 3, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 8, 2018 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 23, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 23, 2018 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 17, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 17, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 13, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 28, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 28, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 28, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 15, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 15, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 22, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 22, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 22, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 22, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 2, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 1, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 1, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 1, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 11, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 10, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 10, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 27, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 10, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 10, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 29, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 28, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 23, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 23, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 22, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |